Oxford University To Assess Immune Response of COVID-19 Vaccine Among Children

Oxford University: Oxford University has decided on testing and assessing the efficacy of the COVID-19 vaccine among children. It gave an announcement about this vaccine trial on Saturday.

The university developed this vaccine with AstraZeneca, and will be conducting a trial of this sort for the first time. This mid-stage trial will try to determine if this vaccine is effective in children between the age group of 6 to 17.

Oxford University aims to benefit this age group in future vaccine programs

Oxford University has also revealed that it will induct about 300 volunteers for the trial, and will start the inoculation from this month.

Professor of paediatric infection and immunity, and chief investigator of the vaccine trial Andrew Pollard said, "While most children are relatively unaffected by coronavirus and are unlikely to become unwell with the infection, it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination."

Rinn Song, a pediatrician and clinical scientist at the Oxford Vaccine Group said that it was extremely important to collect data on the immune response exhibited by children. This trial has the potential to benifit this age group in future vaccine programs.

AstraZenaca Aims To Produce 3 Billion Vaccine Doses By This Year 

AstraZeneca has decided on manufacturing about 200 million doses of the vaccines each month, which will amount to 3 billion this year. The Oxford University/AstraZeneca vaccine has been hailed for its cheap price and easy distribution by the world.

Recently, Kamala Harris, the Vice President of the United States received the second dose of the Moderna COVID-19 vaccine. Read more about it here